Honeywell International Inc vs Revvity Inc — how do they compare? Honeywell International Inc trades at $233.53 (market cap $72.93B), while Revvity Inc trades at $116.17 (market cap $12.91B). The key difference: Honeywell International Inc is far larger — about 5.6× Revvity Inc's market cap, and Honeywell International Inc pays the higher dividend (1.22%). Which is the better fit depends on your goals.
| HON | RVTY | |
|---|---|---|
Market Cap | $72.93B | $12.91B |
Sector | Industrials | Technology |
52-Week High | $248.79 | $117.75 |
52-Week Low | $188.14 | $82.26 |
Enterprise Value | $97.73B | $15.23B |
Dividend Yield | 1.22% | 0.24% |
Signals from Pluang's Aura AI — not financial advice
Honeywell International Inc. (HON) trades at $232.35, down 4.36% amid disappointing growth guidance from a recent investor event. The stock exhibits bearish technical signals with support near $225, while fundamentals remain solid with a low P/E of 8.85 and strong profitability margins. Recent corporate actions include dividend payments and business divestitures, positioning the company as a focused automation play.
The outlook is mixed: attractive valuation and consistent earnings beats support upside toward the $320.54 consensus target, but near-term sentiment is pressured by growth concerns and technical weakness. Key risks include execution of the portfolio transformation and macroeconomic headwinds affecting industrial demand.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →